Amoy Diagnostics Co., Ltd.

SZSE:300685 Stock Report

Market Cap: CN¥9.2b

Amoy Diagnostics Past Earnings Performance

Past criteria checks 5/6

Amoy Diagnostics has been growing earnings at an average annual rate of 15.2%, while the Biotechs industry saw earnings growing at 7.6% annually. Revenues have been growing at an average rate of 13.2% per year. Amoy Diagnostics's return on equity is 17.4%, and it has net margins of 26.6%.

Key information

15.2%

Earnings growth rate

15.1%

EPS growth rate

Biotechs Industry Growth11.3%
Revenue growth rate13.2%
Return on equity17.4%
Net Margin26.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Amoy Diagnostics (SZSE:300685) Has A Rock Solid Balance Sheet

Dec 19
Amoy Diagnostics (SZSE:300685) Has A Rock Solid Balance Sheet

Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Sep 18
Amoy Diagnostics Co., Ltd.'s (SZSE:300685) Earnings Haven't Escaped The Attention Of Investors

Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Aug 23
Are Investors Undervaluing Amoy Diagnostics Co., Ltd. (SZSE:300685) By 23%?

Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

May 27
Amoy Diagnostics' (SZSE:300685) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Apr 24
Earnings Report: Amoy Diagnostics Co., Ltd. Missed Revenue Estimates By 6.1%

Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

Apr 18
Amoy Diagnostics (SZSE:300685) Could Easily Take On More Debt

What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Mar 02
What Amoy Diagnostics Co., Ltd.'s (SZSE:300685) 33% Share Price Gain Is Not Telling You

Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Mar 01
Is Amoy Diagnostics Co., Ltd. (SZSE:300685) Worth CN¥22.0 Based On Its Intrinsic Value?

Revenue & Expenses Breakdown

How Amoy Diagnostics makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

SZSE:300685 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,184315426217
30 Jun 241,128279424218
31 Mar 241,082268402215
31 Dec 231,044261390203
30 Sep 23951213383204
30 Jun 23908301378189
31 Mar 23831267364173
01 Jan 23842264367175
30 Sep 22871287395168
30 Jun 22911218390166
31 Mar 22949250388162
01 Jan 22917240374156
30 Sep 21890231373138
30 Jun 21844211364130
31 Mar 21811198356127
31 Dec 20728180339115
30 Sep 20650153308115
30 Jun 20595138292106
31 Mar 2055012928496
31 Dec 1957813529494
30 Sep 1954114026587
30 Jun 1950213524186
31 Mar 1946913421585
31 Dec 1843912720178
30 Sep 1839812218669
30 Jun 1838412015684
31 Mar 1835710316164
31 Dec 173309415751
30 Sep 173158216339
30 Jun 17288781930
31 Mar 17258671800
31 Dec 16253671810
30 Jun 16220421680
31 Mar 16198321570
31 Dec 15177211470
31 Dec 1410719820
31 Dec 137422520

Quality Earnings: 300685 has high quality earnings.

Growing Profit Margin: 300685's current net profit margins (26.6%) are higher than last year (22.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 300685's earnings have grown by 15.2% per year over the past 5 years.

Accelerating Growth: 300685's earnings growth over the past year (47.7%) exceeds its 5-year average (15.2% per year).

Earnings vs Industry: 300685 earnings growth over the past year (47.7%) exceeded the Biotechs industry 1.3%.

Return on Equity

High ROE: 300685's Return on Equity (17.4%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 20:07
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Amoy Diagnostics Co., Ltd. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yolanda YinChina Galaxy International Securities (Hong Kong)
Pei ChengChina Galaxy Securities Co., Ltd.
Jin ZhangChina International Capital Corporation Limited